The medication for the treatment of ulcers and gastritis :: Consumers survey results of for 1 quarter of 2019

Consumers survey results of for 1 quarter of 2019 in category

Digestive system and hepatology / The medication for the treatment of ulcers and gastritis

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.		Phosphalugel (Astellas Europe)	43.75%	5

2.	7	Мовеспазм (Movi Health GmbH)	25.00%	2.86

3.	2	De-Nol (Astellas Europe)	21.88%	2.50

3.	4	Віс-Нол (Farmak)	21.88%	2.50

5.	4	Гастал (Pliva)	18.75%	2.14

6.		Плантаглюцид (Pharmaceutical company “Zdorovya”)	15.63%	1.79

7.	5	Алюмаг (Гродзиский ФЗ Польфа)	12.50%	1.43

7.	5	Вікалін (Arterium Corporation)	12.50%	1.43

9.	3	Альтан (Борщагівський ХФЗ)	9.38%	1.07

9.	5	Гастро-гран (Національна гомеопатична спілка)	9.38%	1.07

9.	6	Гастро-норм (Arterium Corporation)	9.38%	1.07

12.	6	Вікаїр (Arterium Corporation)	6.25%	0.71

13.	3	Гастромакс (Mili Healthcare)	3.13%	0.36

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2019, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.